Can Valacyclovir Delay the Need for Initiation of Human Immunodeficiency Virus (HIV) Treatment in HIV-infected Individuals?
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
This study is a multicentre, randomized, placebo-controlled, fully blinded, clinical trial of
twice daily oral valacyclovir 500mg versus placebo with the goal of delaying the need for
initiating HAART among HIV infected individuals who neither use nor require HAART, and who
have not used chronic suppressive anti-HSV therapy for at least the 6 months prior to study
initiation.